Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

MYLAN INC
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 12 073 M
EBIT 2017 3 324 M
Net income 2017 1 314 M
Debt 2017 13 503 M
Yield 2017 -
Sales 2018 12 676 M
EBIT 2018 3 737 M
Net income 2018 2 031 M
Debt 2018 11 287 M
Yield 2018 -
P/E ratio 2017 14,13
P/E ratio 2018 10,94
EV / Sales2017 2,83x
EV / Sales2018 2,52x
Capitalization 20 668 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom. 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
10/17 MYLAN : to Report Third Quarter 2017 Financial Results on Nov. 6, 2017
10/17 MYLAN : Invalidates Allergan's Patents on Restasis®
10/05 MYLAN : in Partnership with Synthon, Receives Marketing Authorization Approval i..
10/05 MYLAN NV : Mylan, Approval of Copaxone Should Provide an Accretive Boost, Generi..
10/05 MYLAN : Launches First AP-rated Generic Avelox® Injection
10/05 MYLAN : Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-W..
10/04 MYLAN : Provides Support for U.S. Disaster-Relief Efforts
10/04 MYLAN : Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Ti..
10/02 MYLAN : Launches Generic Cancidas® for Injection
09/29 MYLAN : Launches Generic Gleevec® Tablets
More news
Sector news : Pharmaceuticals - NEC
03:09pDJELI LILLY AND : Lilly To Develop Cancer Vaccine Products with CureVac -- Market ..
08:52aDJASTRAZENECA : Breast-Cancer Drug Gets Priority Review From FDA
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
08:24a RECKITT BENCKISER : to form two business units for better focus
10/17 Regeneron-Sanofi drug succeeds mid-stage study
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 42,0 $
Spread / Average Target 9,0%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC20 668
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423